(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to ...

FRANKFURT (Reuters) - Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure treatment Entresto ...

Novartis recently filed a lawsuit against the Food and Drug Administration in a federal court in Washington, D.C., claiming that the FDA's approval of a generic version of Entresto is unlawful, per a ...

Novartis was unsuccessful in convincing a federal court to block MSN Pharmaceuticals from introducing its own version of Novartis' heart-failure drug Entresto, according to a court decision issued on ...

The Third Circuit and Federal Circuit this week turned back Novartis’s requests for injunctions to block a version of its heart failure medication Entresto from generic maker MSN ...

Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. The erosion was obvious. After MSN Pharmaceuticals opened the floodgates to Entresto generics in ...

FRANKFURT (Reuters) -Swiss drugmaker Novartis, on a deal-making spree this year, reported a 6% gain in operating income as growth of its new drugs outpaced stagnant revenue from established heart drug ...

Novartis has signed deals with two major health plans, Cigna and Aetna, to reimburse for its new heart failure drug Entresto, Reuters reported. The deals are among the first publicly announced ...

(RTTNews) - Swiss drug major Novartis (NVS) Monday announced that the US Court of Appeals for the Federal Circuit or CAFC has decided to upheld the validity of the ...